Day: March 11, 2024

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 2023; top-line results expected in 2026 60-patient Phase 2 studies in combination with each of ribociclib and palbociclib are fully enrolled; palazestrant-ribociclib clinical update to be presented at ESMO Breast Cancer Annual Congress 2024, May 15-17, 2024, in Berlin Cash, cash equivalents and marketable securities of $261.8 million as of December 31, 2023SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers,...

Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of $20 to $30 Million LAKE FOREST, Il., March 11, 2024 (GLOBE NEWSWIRE) —  Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the fourth quarter and full year ended December 31, 2023.Financial Highlights (unaudited):        Three Months Ended December 31,   Twelve Months Ended December 31,(in millions, except per share amounts)   2023       2022     2023       2022Net Product Sales (GAAP) $ 32.5     $ 49.9   $ 149.5     $ 155.1Net (Loss) Income (GAAP) $ (57.4 )   $ 88.6   $ (331.9 )   $ 109.6(Loss)...

Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million HOLLISTER, Calif., March 11, 2024 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2023. “Our performance in 2023 validates the difficult but transformative changes we have made over the last twelve months,” said Stephen Gunstream, President and Chief Executive Officer of Teknova. He continued, “Our business has demonstrated its ability to withstand challenging...

AVAILABILITY OF THE 2024 UNIVERSAL REGISTRATION DOCUMENT, THE ANNUAL FINANCIAL REPORT AND THE REPORT ON CORPORATE FINANCE Regulated Information Paris, 11 March 2024 Societe Generale hereby informs the public that the French version of the 2024 Universal Registration Document was filed with the French Financial Markets Authority (AMF) on 11 March 2024. The 2024 Universal Registration Document includes: •         the 2023 annual financial report; and •         the report on corporate governance prepared by the Board of Directors, as well as the related Statutory Auditors’ findings. The annual financial report cross-reference table appears on page 728 of the Universal Registration Document. The report on corporate governance prepared by the Board of Directors, as well as the related Statutory Auditors’ findings, appear respectively on pages...

AVAILABILITY OF THE 2024 UNIVERSAL REGISTRATION DOCUMENT, THE ANNUAL FINANCIAL REPORT AND THE REPORT ON CORPORATE FINANCE Regulated Information Paris, 11 March 2024 Societe Generale hereby informs the public that the French version of the 2024 Universal Registration Document was filed with the French Financial Markets Authority (AMF) on 11 March 2024. The 2024 Universal Registration Document includes: •         the 2023 annual financial report; and •         the report on corporate governance prepared by the Board of Directors, as well as the related Statutory Auditors’ findings. The annual financial report cross-reference table appears on page 728 of the Universal Registration Document. The report on corporate governance prepared by the Board of Directors, as well as the related Statutory Auditors’ findings, appear respectively on pages...